Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 8901 results

  1. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  2. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development

  3. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  4. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG ID6454

    In development Reference number: GID-TA11592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. OCD Obsessive-compulsive disorder and body dysmorphic disorder

    In development Reference number: GID-QS10200 Expected publication date:  16 February 2027

    Quality standard
    In development

  6. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  7. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    Awaiting development Reference number: GID-TA11886 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTE10068 Expected publication date:  06 January 2027

    Health technology evaluations
    In development

  10. Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]

    Awaiting development Reference number: GID-TA11904 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]

    Awaiting development Reference number: GID-TA11905 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Delgocitinib for Chronic Hand Eczema [ID6688]

    Awaiting development Reference number: GID-TA11777 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Suspected sepsis in under 16s: recognition, diagnosis and early management

    In development Reference number: GID-NG10466 Expected publication date:  17 February 2027

    NICE guideline
    In development

  14. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]

    In development Reference number: GID-TA11625 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development